Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICI trial of eplerenone for central serous chorioretinopathy
ISRCTN92746680Phase 3Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Dec 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Central Serous Chorioretinopathy (CSCR) comparing Eplerenone with Placebo (2 arms). Primary endpoint: Best-corrected visual acuity at 12 months. Started Dec 2016; status: completed.
02
Drugs
eplerenone
03
Conditions
Central Serous Chorioretinopathy (CSCR)
Beyond the preview
Go deeper on ISRCTN92746680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN92746680.